Novel Inhibitor of HIV Replication
Structurally unrelated to current anti-viral therapiesHas potent broad spectrum antiviral activity (e.g. treatment of HIV and various enteroviruses)May act through a potentially novel mechanism of action
Treatment for HIV-1 infectionTreatment for a variety of enterovirus infectionsMaybe used to treat drug-resistant variants of HIV-1 infection
UCLA researchers led by Profs. Paul Krogstad and Jun Zuo have identified a novel small molecule inhibitor of HIV-1 replication, as well as a broad spectrum anti-viral for the treatment of a variety of enteroviruses. Additionally this molecule is structurally unrelated to current antiviral therapeutics, and potentially utilizes a novel mechanism of action, and may be useful for variants of HIV that are resistant to current therapies.
State Of Development Researchers have tested this inhibitor in models of HIV-1 and enterovirus infection. Background Virus-borne diseases represent a significant proportion of infectious diseases worldwide. These diseases, including HIV the virus that causes AIDS which affect millions of people, and are often life-threatening, and have enormous economic impacts; the global market for HIV is estimated at ~$11 billion. Thus, drugs targeting a broad spectrum of viral types would have enormous market potential. However, almost all of the commercially available therapies are specific for particular viruses. The few broad-spectrum drugs are effective only against a limited number of viral types. They can also cause debilitating side effects, limiting the dosages to suboptimal levels. A broad spectrum antiviral therapy is essentially absent in the current marketplace, and few broad-spectrum antivirals are past the preclinical stage. Therapeutic approaches to treat a wide range of pathogenic viruses are therefore highly desirable. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 29043/2016-99I-0 Related Cases 2016-99I-0
美国
